Valuation: Novartis AG

Market Cap 275B 242B 229B 207B 389B 26,374B 391B 2,736B 1,057B 13,458B 1,032B 1,009B 43,247B P/E 2026 *
20.4x
P/E 2027 * 17.2x
Enterprise Value 306B 269B 255B 231B 434B 29,405B 436B 3,050B 1,178B 15,005B 1,150B 1,125B 48,218B EV / Sales 2026 *
5.31x
EV / Sales 2027 * 4.93x
Free-Float
91.66%
Yield 2026 *
3.01%
Yield 2027 * 3.14%
1 week+3.97%
Current month-3.14%
1 month-7.22%
3 months-6.70%
6 months-2.53%
Current year+7.63%
1 week 122.2
Extreme 122.2
129.38
1 month 117.32
Extreme 117.32
141.26
Manager TitleAgeSince
Chief Executive Officer 50 2018-01-31
Director of Finance/CFO - 2026-03-15
Compliance Officer 58 2025-04-13
Director TitleAgeSince
Director/Board Member 67 2014-12-31
Director/Board Member 69 2015-12-31
Director/Board Member 61 2015-12-31
Change 5-day change 1-year change 3-year change Capi.($)
+1.48%+3.97%+21.22% - 275B
+0.24%+1.85%+63.31%+117.92% 1,055B
+0.24%+1.03%+49.90%+73.54% 654B
+0.96%+0.85%+19.52%+75.19% 467B
-1.36%-2.58%+38.77%+42.33% 348B
+1.34%+4.53%+22.56%+29.55% 275B
-0.48%-0.54%+12.66%+13.50% 258B
+0.75%+6.06%+52.21%+53.98% 224B
+0.85%+1.00%+35.03%+101.63% 187B
-0.30%-2.98%-28.24%-61.28% 171B
Average +0.27%+0.74%+28.70%+49.60% 404.26B
Weighted average by Cap. +0.26%+1.32%+38.53%+69.97%

Financials

2026 *2027 *
Net sales 57.74B 50.78B 48.02B 43.56B 81.8B 5,543B 82.28B 575B 222B 2,828B 217B 212B 9,089B 61.39B 54B 51.06B 46.31B 86.98B 5,893B 87.48B 611B 236B 3,007B 231B 226B 9,664B
Net income 14.2B 12.49B 11.81B 10.71B 20.11B 1,363B 20.23B 141B 54.59B 695B 53.3B 52.14B 2,234B 15.75B 13.86B 13.1B 11.88B 22.32B 1,512B 22.45B 157B 60.58B 772B 59.15B 57.86B 2,480B
Net Debt 31.58B 27.77B 26.26B 23.82B 44.74B 3,031B 45B 314B 121B 1,547B 119B 116B 4,971B 27.89B 24.52B 23.19B 21.03B 39.5B 2,677B 39.73B 278B 107B 1,366B 105B 102B 4,389B
Logo Novartis AG
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).
Employees
-
Date Price Change
26-09-28 €129.14 +1.48%
26-09-25 €127.26 +0.68%
26-09-24 €126.40 +0.77%
26-09-23 €125.44 +1.51%
26-09-22 €123.58 +0.67%
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
23
Last Close Price
144.55USD
Average target price
152.43USD
Spread / Average Target
+5.45%

Quarterly revenue - Rate of surprise